While the inductive method of scientific research is powerful in disproving hypotheses, it cannot prove them. Repeated efforts failing to disprove a theory tend to reinforce our sense of the validity of the hypothesis. If the hypothesis is associated with added benefits to its proponents then a conditional premise may become a paradigm, or occasionally a dogma. Two examples from breast cancer research are Halsted's contiguous-spread model and the systemic-dissemination model championed by Fisher. Halsted's central premise was that cancer spread centrifugally from the primary tumor to regional lymph nodes, and only afterwards to distant sites. This led to treatments designed to eradicate tumor at the primary site in conjunction with draining regional lymph nodes becoming the paradigm for all cancer treatment. This model was reinforced by its attractiveness to surgeons, because it rewarded technical proficiency and made the surgeon the center of cancer management.
Surgeons who had the temerity to question this premise, such as Geoffrey Keynes in the UK and later Bernard Fisher in the US, were considered heretics. The Halsted model failed to explain distant tumor metastases in patients for whom local regional tumor ablation was successful. Thus, the systemic model emerged, which described tumors of two types: local only or systemic. If the former then only local treatment is needed, but if the latter, dissemination occurs before clinical detection and cure depends on effective systemic therapy. Acceptance of the systemic model was aided and abetted by the resulting central position of the medical oncologist in cancer care. We now appreciate that both hypotheses have limitations and that cancer should be considered a spectrum of disease proclivities, ranging from those whose disease will remain localized to those that appear to have disseminated disease before clinical detection; most breast cancers have a malignant capacity somewhere in between.
Much enthusiasm exists for 'targeted' pharmaceuticals that are expected to be very effective for certain tumors with specific molecular characteristics, while exhibiting limited toxicity. Gleevec ® (imatinib) in chronic myelogenous leukemia is considered to be the prototype of these. While it is still too early to have strong opinions as to the validity and robustness of targeted drugs in other tumors, it is not too early to caution against their enthusiastic and uncritical acceptance. Targeted agents are attractive, and the promise for future designer drugs is enhanced by the advent of the molecular era and modern drug formulation. This can lead to hyperbolic prophesy, such as that attributed by Gina Kolata to Nobelist James Dewey Watson a few years ago, in heralding the transforming power of antiangiogenic treatment on the front page of the New York Times. I read recently in that same newspaper that the success of Herceptin ® (trastuzumab), targeted to HER2 overexpression in certain breast cancers, and Avastin ® (bevacizumab) an antiangiogeneic drug, caused a 50% rise in the stock price of their manufacturer, Genentech, in only a matter of weeks. While it is recognized that group opinion and naive enthusiasm are hallmarks of stock market participants, such behavior can have serious consequences in medical science. The results are promising but we must be careful not to over-promise our patients, the public or ourselves. How these results will change the treatment paradigm is still uncertain. We may wish for them to herald an attractive new paradigm but wishing that something were so does not make it so, but rather deceives us and confounds our thinking. Acceptance of the conditional nature of the scientific method should lead to humility as well as a healthy skepticism when confronting excessive promises. We should leave that to stock-market enthusiasts. 
